High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
| dc.contributor.author | Cook, G | |
| dc.contributor.author | Williams, C | |
| dc.contributor.author | Brown, J | |
| dc.contributor.author | Cairns, D | |
| dc.contributor.author | Cavenagh, J | |
| dc.contributor.author | Snowden, J | |
| dc.contributor.author | Ashcroft, A | |
| dc.contributor.author | Fletcher, M | |
| dc.contributor.author | Parrish, C | |
| dc.contributor.author | Yong, K | |
| dc.contributor.author | Cavet, James | |
| dc.contributor.author | Hunter, H | |
| dc.contributor.author | Bird, J | |
| dc.contributor.author | Chalmers, A | |
| dc.contributor.author | O'Connor, S | |
| dc.contributor.author | Drayson, M | |
| dc.contributor.author | Morris, T | |
| dc.date.accessioned | 2014-07-08T14:28:16Z | |
| dc.date.available | 2014-07-08T14:28:16Z | |
| dc.date.issued | 2014-07 | |
| dc.identifier.citation | High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. 2014, 15 (8):874-85 Lancet Oncol | en |
| dc.identifier.issn | 1474-5488 | |
| dc.identifier.pmid | 24948586 | |
| dc.identifier.doi | 10.1016/S1470-2045(14)70245-1 | |
| dc.identifier.uri | http://hdl.handle.net/10541/322590 | |
| dc.description.abstract | Relapsed multiple myeloma has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been fully defined. We aimed to compare high-dose melphalan plus salvage ASCT with cyclophosphamide in patients with relapsed multiple myeloma who had previously undergone ASCT. | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to The lancet oncology | en |
| dc.title | High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. | en |
| dc.type | Article | en |
| dc.contributor.department | St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, UK. | en |
| dc.identifier.journal | The Lancet Oncology | en |
| html.description.abstract | Relapsed multiple myeloma has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been fully defined. We aimed to compare high-dose melphalan plus salvage ASCT with cyclophosphamide in patients with relapsed multiple myeloma who had previously undergone ASCT. |